

Mexico City, October 3rd, 2013

GENOMMA LAB PLACES DEBT CERTIFICATES FOR \$2.00 BILLION PESOS

Genomma Lab Internacional S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”), announced today that it successfully completed the issuance of debt certificates (Certificados Bursátiles LAB’13-2) amounting to \$2.00 billion pesos, its second debt securities issuance in the Mexican market.

The debt certificates issued have a maturity of four years, ending in October 2017, and will pay interest every 28 days at a coupon rate of TIIE (Tasa de Interés Interbancaria de Equilibrio) 28 days plus 0.70 percentage points. The certificates were rated AA (mex)” by Fitch Ratings and “HR AA” by HR Ratings.

The underwriters that jointly participated in the offer were Acciones y Valores Banamex, S.A. de C.V., Casa de Bolsa Integrante del Grupo Financiero Banamex and Casa de Bolsa Santander, S.A. de C.V., Grupo Financiero Santander México.

It is important to highlight that the resources obtained will not increase the Company’s debt level, since they will be used to refinance existing debt with financial institutions, improving importantly its maturity profile and decreasing its cost.

“We are very satisfied with this second issuance of “Certificados Bursátiles”, which had a higher demand than the first one, done in July of this year, proving the Company has achieved a good positioning in the Mexican debt market”, commented Rodrigo Herrera, CEO and Chairman of the Board.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

Contact:

Investor Relations
Tel: +52 (55) 5081 0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.